Peer-reviewed veterinary case report
New combined pill vs powder meds for dogs with mitral valve disease
By Park, Jiyoung et al.·Published in Frontiers in veterinary science·2025·Hyun Changbaig Animal Heart Institute, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical evaluation of a novel fixed-dose combination tablet (SentorphilForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study.
- Species:
- dog
Plain-English summary
A group of 60 small-breed dogs with myxomatous mitral valve disease (a common heart problem in older dogs) was treated with either a new fixed-dose tablet called SentorphilForteGold or a mixture of powdered medications. Over 56 days, both treatments helped improve symptoms like exercise intolerance, appetite, and coughing, but the dogs on the new tablet showed quicker and more lasting improvements. Blood tests and heart evaluations indicated that both treatments were safe and effective, with the tablet group experiencing a greater reduction in a specific heart-related biomarker. Overall, the fixed-dose tablet proved to be a promising option for managing this heart condition in dogs.
People also search for: dog heart disease treatment · myxomatous mitral valve disease in dogs · SentorphilForteGold for dogs
Abstract
INTRODUCTION: Myxomatous mitral valve disease (MMVD) is a prevalent cardiac condition in older, small-breed dogs, often managed with multiple medications. Traditional administration involves compounded powdered mixtures, which may lead to dosing inaccuracies and reduced compliance. METHODS: In a randomized, double-blind clinical trial, 60 client-owned dogs diagnosed with ACVIM stage C MMVD were assigned to receive either a novel fixed-dose combination tablet (SentorphilForteGold) or a compounded powdered mixture of torsemide, pimobendan, enalapril, and spironolactone. Treatments were administered twice daily over 56 days. Clinical signs, blood chemistry, electrolyte levels, thoracic radiography, echocardiography, and biomarkers (NT-proBNP, SDMA, and cPL) were evaluated at baseline and on days 7, 14, 28, and 56. RESULTS: Both groups exhibited significant improvements in clinical signs, including exercise intolerance, appetite, respiratory effort, and coughing, with the ForteGold group showing earlier and more sustained responses. Blood chemistry and electrolyte levels remained within normal ranges, indicating a favorable safety profile. Radiographic assessments revealed a gradual decrease in vertebral heart score and normalization of lung fields by Day 56 in both groups. Echocardiographic parameters (LA/Ao, LVIDd/Ao, MVE) improved significantly, with the ForteGold group demonstrating earlier enhancements. NT-proBNP levels decreased in both groups, with a more pronounced reduction in the ForteGold group. No significant changes were observed in SDMA and cPL levels, suggesting stable renal and pancreatic functions. DISCUSSION: The fixed-dose combination tablet (SentorphilForteGold) offers a clinically effective and safer alternative to compounded powdered medications for managing MMVD in dogs. Its formulation ensures accurate dosing, improved owner compliance, and enhanced clinical outcomes. Further studies with larger populations and extended follow-up periods are warranted to confirm these findings.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40874198/